Abstract
Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis. Clinical studies have demonstrated association between different blood leukocytes and mortality and FVC decline. Here we question which blood leukocyte levels are specifically associated with progression of fibrosis, measured by accumulation of fibrosis on CT scan using a standardised automated method.
Methods Using the CALIPER (Computer-Aided Lung Informatics for Pathology Evaluation and Rating) CT algorithm, we determined the correlation between different blood leukocytes (<4 months from CT) and total lung fibrosis (TLF) scores, pulmonary vessel volume (PVV), FVC% and TLCO% at baseline (n=171) and with progression of fibrosis (n=71), the latter using multivariate Cox regression.
Results Neutrophils (but not monocyte or lymphocytes) correlated with extent of lung fibrosis (TLF/litre) (r=0.208, p=0.007), PVV (r=0.259, p=0.001), FVC% (r=-0.127, p=0.029) at baseline. For the 71 cases with repeat CT; median interval between CTs was 25.9 (16.8-39.9) months. Neutrophil but not monocyte levels are associated with increase in TLF/litre [HR 2.66, 95%CI, 1.35-5.25, p=0.005].
Conclusion Our study shows that neutrophil rather than monocyte levels correlated with quantifiable increase in fibrosis on imaging of the lungs in IPF, suggesting its relative greater contribution to progression of fibrosis in IPF.
WHAT IS ALREADY KNOWN ON THIS TOPIC Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic condition. Recently, several human studies have implicated blood leukocyte levels (monocyte, neutrophil and lymphocyte) with FVC decline and mortality. However, direct association between leukocytes and progression of fibrosis using quantitative CT analysis has not been explored.
WHAT THIS STUDY ADDS This study explored the association between blood monocytes, neutrophils and lymphocytes against increase in fibrosis over time, measured using a quantitative CT algorithm, CALIPER. We show that levels of blood neutrophil and lymphocytes but not monocytes were associated with greater risk of progression of fibrosis.
HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY Our study shows that neutrophil rather than monocyte levels correlated with quantifiable increase in fibrosis on imaging of the lungs in IPF, suggesting its relative greater contribution to progression of fibrosis in IPF.
Competing Interest Statement
Andrew Achaiah, Emily Fraser, Rachel Benamore, Ling-Pei Ho and Rachel Hoyles report no relevant conflict of interests. Peter Saunders has received consultancy fees from Trevi Therapeutics, and lecture fees from Boehringer Ingelheim, but no other conflict of interest.
Funding Statement
The study was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). LPH is supported in part by MRC UK (MC_UU_00008/1). Correspondence to Prof Ling-Pei Ho (ling-pei.ho{at}imm.ox.ac.uk).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was part of a study examining factors associated with progression of IPF (ethical approval 14/SC/1060 from the Health Research Authority and South-Central National Research Ethics Service).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
